KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

2008 ◽  
Vol 5 (10) ◽  
pp. 2140-2155 ◽  
Author(s):  
Christian G. Hartinger ◽  
Michael A. Jakupec ◽  
Stefanie Zorbas-Seifried ◽  
Michael Groessl ◽  
Alexander Egger ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Anticancer Agent ◽  
Preclinical Development ◽  
Tumor Patients ◽  
Clinical Phase ◽  
Redox Active

ChemInform Abstract: KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

ChemInform ◽  
2009 ◽  
Vol 40 (3) ◽  
Author(s):  
Christian G. Hartinger ◽  
Michael A. Jakupec ◽  
Stefanie Zorbas-Seifried ◽  
Michael Groessl ◽  
Alexander Egger ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Anticancer Agent ◽  
Preclinical Development ◽  
Tumor Patients ◽  
Clinical Phase ◽  
Redox Active

scholarly journals Results from clinical phase I study on breast tumor ablation with dedicated breast MR-HIFU system

2015 ◽  
Vol 3 (S1) ◽  
Author(s):  
Floor Knuttel ◽  
Roel Deckers ◽  
Laura Merckel ◽  
Gerald Schubert ◽  
Max Kohler ◽  
...  
Keyword(s):  
Phase I ◽  
Breast Tumor ◽  
Phase I Study ◽  
Tumor Ablation ◽  
Clinical Phase ◽  
Breast Mr

scholarly journals Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

2015 ◽  
Vol 75 (3) ◽  
pp. 579-586 ◽  
Author(s):  
T. C. Chang ◽  
H. S. Shiah ◽  
C. H. Yang ◽  
K. H. Yeh ◽  
A. L. Cheng ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumor ◽  
Phase I Study ◽  
Advanced Solid Tumor ◽  
Tumor Patients ◽  
Nanoliposomal Irinotecan

Myocardial Perfusion and MR Angiography of Chest with SH U 555 C: Results of Placebo-controlled Clinical Phase I Study

Radiology ◽  
2004 ◽  
Vol 231 (2) ◽  
pp. 474-481 ◽  
Author(s):  
Peter Reimer ◽  
Christoph Bremer ◽  
Thomas Allkemper ◽  
Matthias Engelhardt ◽  
Marianne Mahler ◽  
...  
Keyword(s):  
Myocardial Perfusion ◽  
Phase I ◽  
Phase I Study ◽  
Mr Angiography ◽  
Clinical Phase

scholarly journals Significant Increase in Cytotoxic T Lymphocytes and Natural Killer Cells by Triphala: A Clinical Phase I Study

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Pratya Phetkate ◽  
Tanawan Kummalue ◽  
Yaowalak U-pratya ◽  
Somboon Kietinun
Keyword(s):  
T Cells ◽  
Side Effects ◽  
Natural Killer Cells ◽  
Phase I ◽  
Natural Killer ◽  
Phase I Study ◽  
Cytotoxic T Cells ◽  
Killer Cells ◽  
Clinical Phase ◽  
Hiv Aids

Background. Searching for drugs or herbal formulations to improve the immunity of HIV/AIDS positive people is an important issue for researchers in this field. Triphala, a Thai herbal formulation, is reported to have immunomodulatory effects in mice. However, it has not yet been investigated for immunostimulatory and side effects in healthy human volunteers.Objective. To evaluate the immunostimulatory and side effects of Triphala in a clinical phase I study.Materials and Methods. All volunteers took Triphala, 3 capsules per day for 2 weeks. Complete physical examination, routine laboratory analysis, and immunological studies were performed before ingestion and after initial meeting for 4 consecutive weeks.Results. We found that Triphala demonstrated significant immunostimulatory effects on cytotoxic T cells (CD3−CD8+) and natural killer cells (CD16+CD56+). Both of them increased significantly when compared with those of the control samples. However, no significant change in cytokine secretion was detected. All volunteers were healthy and showed no adverse effects throughout the duration of the study.Conclusion. Triphala has significant immunostimulatory effects on cellular immune response, especially cytotoxic T cells and natural killer cells. Increases in the absolute number of these cells may provide a novel adjuvant therapy for HIV/AIDS positive people in terms of immunological improvement.

Sign in / Sign up

Export Citation Format

Share Document